DURHAM, N.C., June 27, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) that will resolve the Government Accountability Office (GAO) review of the recent sole source contract awarded to SIGA Technologies, Inc. for the development and delivery of a smallpox antiviral to the Strategic National Stockpile. This agreement allows BARDA the opportunity to competitively procure a second smallpox antiviral, consistent with the U.S. government's long-stated strategy of having two smallpox antiviral drugs for protecting the public against the intentional or unintentional release of the smallpox virus.
The original SIGA sole source contract was for a base amount of 1.7 million treatment courses of smallpox antiviral as well as an optional 12 million additional treatment courses. According to BARDA's initial justification for this sole source contract, the 12 million additional courses were designated for individuals who had "an uncertain immune response to smallpox." BARDA has concluded that it is in the U.S. government's interest to delete the 12 million optional courses from the SIGA contract. Accordingly, Chimerix has withdrawn its GAO protest of the SIGA sole source contract.
Chimerix's lead product CMX001 is being developed as a broad spectrum antiviral with particular emphasis on the ability to treat immunocompromised patients, which includes individuals infected with smallpox. A separate BARDA procurement of additional treatment courses at a future date will give Chimerix the opportunity to compete for a contract for the second smallpox antiviral. This resolution serves the nation's overall interests to have two antiviral drugs for use against smallpox.
"We are pleased
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved